Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-652 + Corticosteroids for Lower GI aGVHD
NCT02406651Phase 2Completed
- Sponsor
- Evive Biotech
- Start
- May 2016
- Primary completion
- Apr 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eflepedocokin alfa in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Evive Biotech. Primary endpoint: The Number of Participants With Lower Gastrointestinal Acute Graft-Versus-Host-Disease Treatment Response Rate on Day 28. Started May 2016; status: completed.
02
Drugs
eflepedocokin alfa
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02406651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406651.